U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07467759) titled 'Benzydamine for Radiation-Induced Oral Mucositis in Patients Receiving High-Dose Radiotherapy' on March 08.
Brief Summary: This single-center, open-label, randomized clinical trial evaluates the effect of 0.15% benzydamine hydrochloride (Difflam) oral spray on the severity of radiation-induced oral mucositis in patients with head and neck cancer receiving high-dose radiotherapy (>=50 Gy) without concurrent chemotherapy. Oral mucositis is a common and clinically significant complication of radiotherapy that can cause pain, difficulty swallowing, nutritional impairment, and treatment interruption.
Participants are randomly assigned ...